Kuros Biosciences received FDA 510(k) clearance to extend its MagnetOs Putty indications to use as a standalone bone graft in the extremities and pelvis.
Biologics
Kuros Biosciences' MagnetOs is a suitable alternative to autograft for spinal fusion when used as a standalone graft, according to an animal study in JOR Spine.
Carmell Therapeutics is a biotechnology company focused on plasma-based bioactive materials.
The global spinal biologics market is predicted to grow at a 3.75 percent compound annual growth rate, reaching $2.36 billion by 2021, according to a Research Cosmos report.
Anika Therapeutics resumed distribution of its solid hyaluronic acid-based treatments after a voluntary, non-safety related recall in the second quarter.
AlloSource received a U.S. patent for its proprietary method to create ProChondrixCR, the company's fresh cryopreserved osteochondral allograft.
Bio2 Technologies is an orthobiologics company.
The global spine biologics market is projected to grow at a 3.5 percent compound annual growth rate to reach $2.72 billion by the end of 2025, according to a Market Reports World report.
Grand Junction, Colo.-based Vail-Summit Orthopaedics & Neurosurgery is using injectable plasma and stem cells to treat sports-related ligament and tendon injuries, according to an article written by William Sterett, MD, in Summit Daily.
Regenerative medicine company Osiris Therapeutics named Samson Tom as president and CEO.
